A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

S Ackler, MJ Mitten, J Chen, J Clarin, K Foster, S Jin, DC Phillips, S Schlessinger, B Wang, JD Leverson, ER Boghaert, Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo British Journal of Pharmacology. ,vol. 167, pp. 881- 891 ,(2012) , 10.1111/J.1476-5381.2012.02048.X

Robert E Thurman, Eric Rynes, Richard Humbert, Jeff Vierstra, Matthew T Maurano, Eric Haugen, Nathan C Sheffield, Andrew B Stergachis, Hao Wang, Benjamin Vernot, Kavita Garg, Sam John, Richard Sandstrom, Daniel Bates, Lisa Boatman, Theresa K Canfield, Morgan Diegel, Douglas Dunn, Abigail K Ebersol, Tristan Frum, Erika Giste, Audra K Johnson, Ericka M Johnson, Tanya Kutyavin, Bryan Lajoie, Bum-Kyu Lee, Kristen Lee, Darin London, Dimitra Lotakis, Shane Neph, Fidencio Neri, Eric D Nguyen, Hongzhu Qu, Alex P Reynolds, Vaughn Roach, Alexias Safi, Minerva E Sanchez, Amartya Sanyal, Anthony Shafer, Jeremy M Simon, Lingyun Song, Shinny Vong, Molly Weaver, Yongqi Yan, Zhancheng Zhang, Zhuzhu Zhang, Boris Lenhard, Muneesh Tewari, Michael O Dorschner, R Scott Hansen, Patrick A Navas, George Stamatoyannopoulos, Vishwanath R Iyer, Jason D Lieb, Shamil R Sunyaev, Joshua M Akey, Peter J Sabo, Rajinder Kaul, Terrence S Furey, Job Dekker, Gregory E Crawford, John A Stamatoyannopoulos, None, The accessible chromatin landscape of the human genome Nature. ,vol. 489, pp. 75- 82 ,(2012) , 10.1038/NATURE11232

Matthew S. Davids, Anthony Letai, Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer Journal of Clinical Oncology. ,vol. 30, pp. 3127- 3135 ,(2012) , 10.1200/JCO.2011.37.0981

Suzanne Cory, Jerry M. Adams, Killing cancer cells by flipping the Bcl-2/Bax switch Cancer Cell. ,vol. 8, pp. 5- 6 ,(2005) , 10.1016/J.CCR.2005.06.012

Loren D. Walensky, From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia Journal of Clinical Oncology. ,vol. 30, pp. 554- 557 ,(2012) , 10.1200/JCO.2011.37.9339

F Basit, S Cristofanon, S Fulda, Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes Cell Death & Differentiation. ,vol. 20, pp. 1161- 1173 ,(2013) , 10.1038/CDD.2013.45

Roy S. Herbst, Stanley R. Frankel, Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide) A Rational Therapeutic to Enhance Apoptosis in Therapy of Lung Cancer Clinical Cancer Research. ,vol. 10, ,(2004) , 10.1158/1078-0432.CCR-040018

Abid R. Mattoo, David J. Fitzgerald, Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines. International Journal of Cancer. ,vol. 132, pp. 978- 987 ,(2013) , 10.1002/IJC.27732

J ADAMS, S CORY, Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Current Opinion in Immunology. ,vol. 19, pp. 488- 496 ,(2007) , 10.1016/J.COI.2007.05.004

Matthew S. Davids, Anthony Letai, ABT-199: taking dead aim at BCL-2. Cancer Cell. ,vol. 23, pp. 139- 141 ,(2013) , 10.1016/J.CCR.2013.01.018